ClinicalTrials.gg
RecruitingNCT06416995Updated May 16, 2024

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

An observational study in Preeclampsia, Gestational Hypertension and Gestational Diabetes, sponsored by Umraniye Education and Research Hospital. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Umraniye Education and Research Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
88
Ages
18 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Pre-Eclampsia with a site in Turkey — 11 open to participants now, 11 under way, none of them phase 3. Pre-Eclampsia · Turkey.

Planned enrollment
20th of 31
88 · median 96
Started
2023
with 7 others
Observational
31 of 50
6 open now
Primary completion
2024-11
later than 2 of 10 live
Registered
31st of 50
by date

Among the 50 studies in Pre-Eclampsia with a site in Turkey, this one is the 20th largest by planned enrollment of the 31 observational ones that give a count, is one of 8 that started in 2023, is one of 31 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 31st registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

11 of the 50 studies in Pre-Eclampsia with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 39 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Pre-Eclampsia with a site in Turkey, or all of them as a file.
02

Study summary

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.

Read the detailed description

Previous animal model studies in the literature have shown that vasohibin-1 released in endothelial cells inhibits angiogenesis, while vasohibin-2 stimulates angiogenesis. Additionally, immunohistochemical studies have shown that vasohibin-2 plays a role in the cellular fusion of trophoblasts in the placenta to form syncytiotrophoblasts.

Studies in the literature have shown that cardiotrophin-1 is expressed in cardiac myocytes and vascular endothelial cells and stimulates the synthesis and secretion of endothelin-1 in endothelial cells through the gp130 signaling pathway. Since endothelin 1 plays an important role in the regulation of vascular tone, cardiotrophin-1 can be considered to act as an endothelium-derived biological factor, possibly involved in the regulation of vascular tone under normal physiological conditions or secondary to pathological processes.

Studies in the literature have shown that maternal serum endocan levels are higher in pregnant women whose pregnancies were complicated by preeclampsia than in normotensive pregnant women, and that the endocan molecule may be effective in the etiopathogenesis of preeclampsia, especially if it develops early.

In the light of this above-mentioned information, we aim to investigate whether serum vasohibin-1, vasohibin-2, cardiotrophin-1 and endocan concentrations measured during the 11th to 14th weeks of pregnancy can be used to predict preeclampsia, gestational hypertension, fetal growth restriction, preterm birth and gestational diabetes mellitus.

03

Conditions studied

  • Preeclampsia
  • Gestational Hypertension
  • Gestational Diabetes
  • Preterm Birth
  • Fetal Growth Retardation
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Pregnant women with a singleton pregnancy who are between 11 and 14 weeks of gestation, who do not smoke, and do not have any systemic disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group
  • Those with singleton pregnancy
  • Those who did not conceive pregnancy with assisted reproductive treatment methods
  • Those who do not have any pregestational diseases
  • Those who do not have any uterine anomalies

Exclusion criteria

Exclusion Criteria:

  • Smokers
  • Those who are in the high-risk group with the first trimester screening test
  • Those with multiple pregnancies
  • Those who conceive with assisted reproductive treatment methods
  • Those who had any disease before pregnancy
  • Those who have any uterine anomalies
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
88 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control Group

    Pregnant women who do not have any pregestational disease, who gave a blood sample in the first trimester for the study, who did not develop any pregnancy-related disease during their pregnancy, and who gave birth at term.

    Diagnostic Test: first trimester serum diagnostic test

  • Adverse Perinatal Outcome Group

    Pregnant women who do not have any pregestational disease and who gave a blood sample in the first trimester for the study and who develop preeclampsia, gestational hypertension, preterm birth, fetal growth restriction, and gestational diabetes mellitus in the later weeks of pregnancy.

    Diagnostic Test: first trimester serum diagnostic test

Interventions

  • Diagnostic testfirst trimester serum diagnostic test

    First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes

06

What researchers measure

Primary outcomes

  1. Usability of serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations in predicting adverse perinatal outcomes

    Usability of serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations in predicting adverse perinatal outcomes

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Ümraniye Eğitim ve Araştırma Hastanesi
    Istanbul, Ümraniye 34764, Turkey
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2024, 20 months after the start.

Of 191 non-industry observational studies under Pre-Eclampsia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 20 months is below that.

Counting every sponsor, half of 200 studies reached it within 30 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2024
First posted
May 16, 2024
StartActual
Mar 3, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 30, 2024
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06416995
Lead sponsor
Umraniye Education and Research Hospital
Responsible party
ibrahim kale (Associate professor, Umraniye Education and Research Hospital) — Principal investigator
First posted
May 16, 2024
Start date
Mar 3, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
May 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion